Harrow Health (HROW) Price & Analysis

Q: What was Harrow Health Inc’s price range in the past 12 months?

Harrow Health Inc lowest stock price was $20.85 and its highest was $59.23 in the past 12 months.

Q: What is Harrow Health Inc’s market cap?

Harrow Health Inc’s market cap is $1.23B.

Q: When is Harrow Health Inc’s upcoming earnings report date?

Harrow Health Inc’s upcoming earnings report date is Aug 11, 2025 which is in 3 days.

Q: How were Harrow Health Inc’s earnings last quarter?

Harrow Health Inc released its earnings results on May 08, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.046 by -$0.454.

Q: Is Harrow Health Inc overvalued?

According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Harrow Health Inc pay dividends?

Harrow Health Inc does not currently pay dividends.

Q: What is Harrow Health Inc’s EPS estimate?

Harrow Health Inc’s EPS estimate is <0.01.

Q: How many shares outstanding does Harrow Health Inc have?

Harrow Health Inc has 36,699,554 shares outstanding.

Q: What happened to Harrow Health Inc’s price movement after its last earnings report?

Harrow Health Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went up 3.434%.

Q: Which hedge fund is a major shareholder of Harrow Health Inc?

Currently, no hedge funds are holding shares in HROW

Compare

396 Followers

HROW Stock Chart & Stats

Day’s Range― - ―

52-Week Range$20.85 - $59.23

Previous CloseN/A

Volume51.77K

Average Volume (3M)421.97K

Market Cap

$1.23B

Enterprise Value$1.12B

Total Cash (Recent Filing)$66.73M

Total Debt (Recent Filing)$230.01M

Price to Earnings (P/E)―

Beta1.85

Next Earnings

Aug 11, 2025

EPS Estimate

<0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.50

Shares Outstanding36,699,554

10 Day Avg. Volume406,819

30 Day Avg. Volume421,971

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.91

Enterprise Value/Revenue5.24

Enterprise Value/Gross Profit7.03

Enterprise Value/Ebitda59.84

Forecast

1Y Price Target

$60.00

Price Target Upside80.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Acquisition And Commercial RightsHarrow has acquired exclusive U.S. commercial rights to two ophthalmology biosimilars, strengthening its commercial portfolio of ophthalmic drugs.

Strategic PartnershipsHarrow announced a definitive agreement with Samsung Bioepis for the exclusive U.S. commercial rights to two ophthalmology biosimilars, including BYOOVIZ and OPUVIZ.

Bears Say

Product Development RisksRisks include lower-than-projected market uptake of products and the inability to develop and secure regulatory approval of pipeline products.

Regulatory And Market RisksThe U.S. launch date of OPUVIZ is yet to be determined due to ongoing litigation involving biosimilar manufacturers.

Harrow Health News

Harrow enters commercialization agreement with Samsung Bioepis for biosimilars

Harrow (HROW) announced that it has entered into a definitive agreement with Samsung Bioepis to secure the exclusive...

22d ago

HROW

CoreWeave initiated, Texas Instruments upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

28d ago

AMC

BYD

Video: Capricor plunges after CRL, Performance Foods up after seeing interest

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

28d ago

VFC

CAPR

Harrow initiated with an Overweight at Cantor Fitzgerald amid path to growth

Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Harrow (HROW) with an Overweight rating and $76 price target...

28d ago

HROW

Harrow initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Harrow (HROW) with an Overweight rating and $76 price target Published first on...

28d ago

HROW

Harrow Health’s Strategic Acquisition and Market Positioning Justify Buy Rating

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on HROW stock, giving a Buy rating...

22d ago

HROW

Harrow Health Approves Key Proposals at Annual Meeting

Harrow Health ( ($HROW) ) has provided an announcement. On June 18, 2025, Harrow Health held its Annual...

2M ago

HROW

Harrow management to meet virtually with Lake Street

Virtual Meeting to be held on June 24 hosted by Lake Street. Published first on TheFly – the...

2M ago

HROW

Harrow initiated with a Buy at BTIG

BTIG initiated coverage of Harrow (HROW) with a Buy rating and $62 price target The company has 16...

2M ago

HROW

Harrow Health’s Strategic Expansion and Growth Potential in Branded Pharmaceuticals

Harrow Health (HROW) has received a new Buy rating, initiated by William Blair analyst, Lachlan Hanbury Brown. Lachlan...

2M ago

HROW

Harrow initiated with an Outperform at William Blair

William Blair analyst Lachlan Hanbury-Brown initiated coverage of Harrow (HROW) with an Outperform rating and $63 fair value...

2M ago

HROW

Harrow acquires U.S. commercial rights to BYQLOVI 0.05% from Formosa

Harrow (HROW) announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI 0.05%....

2M ago

HROW

Harrow acquires commercial rights for Byqlovi 0.05%

Harrow (HROW) and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial...

2M ago

HROW

Harrow Health’s Earnings Call: Strong Growth Amid Challenges

Harrow Health (($HROW)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

HROW

HROW FAQ

What was Harrow Health Inc’s price range in the past 12 months?

Harrow Health Inc lowest stock price was $20.85 and its highest was $59.23 in the past 12 months.

What is Harrow Health Inc’s market cap?

Harrow Health Inc’s market cap is $1.23B.

When is Harrow Health Inc’s upcoming earnings report date?

Harrow Health Inc’s upcoming earnings report date is Aug 11, 2025 which is in 3 days.

How were Harrow Health Inc’s earnings last quarter?

Harrow Health Inc released its earnings results on May 08, 2025. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.046 by -$0.454.

Is Harrow Health Inc overvalued?

According to Wall Street analysts Harrow Health Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Harrow Health Inc pay dividends?

Harrow Health Inc does not currently pay dividends.

What is Harrow Health Inc’s EPS estimate?

Harrow Health Inc’s EPS estimate is <0.01.

How many shares outstanding does Harrow Health Inc have?

Harrow Health Inc has 36,699,554 shares outstanding.

What happened to Harrow Health Inc’s price movement after its last earnings report?

Harrow Health Inc reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went up 3.434%.

Which hedge fund is a major shareholder of Harrow Health Inc?

Currently, no hedge funds are holding shares in HROW

Harrow Health Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.23%

Trailing 12-Months

Asset Growth

23.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Harrow Health Inc

Harrow Health, Inc. (HROW) is a pharmaceutical company primarily focused on the development, production, and commercialization of innovative medications, especially in the ophthalmic sector. The company is dedicated to providing specialty pharmaceutical products and services to eyecare professionals, enhancing patient care through its proprietary compounding formulations and FDA-approved products.

Harrow Health (HROW) Earnings & Revenues

Historic Earnings Reports

HROW Company Deck

HROW Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Harrow demonstrated strong revenue growth and cash flow, along with successful strategic initiatives in product launches and market access. However, the quarter was marred by seasonal revenue weakness and significant one-time expenses. The company's outlook remains positive with expectations for growth in the remainder of the year.View all HROW earnings summaries

HROW Stock 12 Month Forecast

Average Price Target

$60.00

▲(80.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","50":"$50","77":"$77","36.5":"$36.5","63.5":"$63.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$76.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,36.5,50,63.5,77],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.23,34.673846153846156,38.11769230769231,41.56153846153846,45.005384615384614,48.449230769230766,51.89307692307692,55.33692307692307,58.780769230769224,62.224615384615376,65.66846153846153,69.11230769230768,72.55615384615385,{"y":76,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.23,33.44307692307692,35.65615384615385,37.86923076923077,40.082307692307694,42.29538461538461,44.50846153846154,46.72153846153846,48.934615384615384,51.14769230769231,53.36076923076923,55.57384615384615,57.786923076923074,{"y":60,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.23,32.058461538461536,32.886923076923075,33.715384615384615,34.543846153846154,35.37230769230769,36.20076923076923,37.02923076923077,37.85769230769231,38.68615384615384,39.51461538461538,40.34307692307692,41.17153846153846,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >